LEADS BIOLABS-B (9887.HK) fluctuates at a high level, with increasing divergence in sector capital

On January 23rd, LEADS BIOLABS-B rebounded in the early session but fell back in the afternoon, with short-term funds showing a reduction in positions at high levels. The biotechnology sector has shown significant volatility this week, with industry news such as new drug progress and collaboration dynamics frequently becoming market hotspots. There were rumors that the company's new drug project was approved to enter the clinical stage, but overall sector funds did not see significant inflows, leading to divergent trading sentiment. The market generally believes that the positive dynamics of new drugs are at a stage, but due to factors such as tightening industry regulations, the motivation for funds to chase higher is limited. The stock price has frequently oscillated at high levels, with intraday trading volume gradually shrinking, indicating weak upward momentum. Although the technical trend maintains a bullish pattern, the decline in trading volume dilutes technical signals, and funding discrepancies persist. The focus is on whether short-term trading volume can effectively rebound; if there are no further catalysts in the news, the space for breaking new highs is limited. Conversely, if the industry sees new developments, it may bring temporary relief. In the context of high-level oscillation, it is necessary to closely monitor changes in main funds and the overall linkage of the sector. It is recommended that investors adopt a defensive approach, grasp the rhythm in conjunction with sector news, and strictly control position management